Krüger M, van Beuningen D, Streffer C
Institut für Medizinische Strahlenbiologie, Universitätsklinikum Essen.
Strahlenther Onkol. 1990 Sep;166(9):626-31.
The survival rate of human melanoma cells after X-ray irradiation, treatment with adriamycin derivatives and combined treatment with X-rays and adriamycin derivatives was measured by means of the colony formation test. After X-ray irradiation the melanoma cells showed a high resistance for cell survival. In all tests the Be11-cells were more resistant than MeWo-cells. On combined exposure especially with higher doses of adriamycin derivatives, both cell lines showed the interesting effect, that with increasing concentration the survival rate decreased whereas the D(o) increased. Aclacinomycin-A (ACM-A) and Pirarubicin reduced recovery processes after X-ray irradiation. Therefore Be11-cells showed a four times higher DMF (dosis modifying factor) after ACM-A-treatment than MeWo-cells. Low ACM-A-concentrations combined with low X-ray doses showed on both cell lines supraadditive effects. The effect of pirarubicin was in most of the tests only additive. Compared with ACM-A, pirarubicin was less cytotoxic, showed a larger therapeutic range, caused a smaller D(o) and Dq and had a supraadditive effect in low concentrations on both cell lines. For clinical combined therapy with patients ACM-A is probably better suited than pirarubicin.
通过集落形成试验测定人黑色素瘤细胞在X射线照射、阿霉素衍生物处理以及X射线与阿霉素衍生物联合处理后的存活率。X射线照射后,黑色素瘤细胞显示出较高的细胞存活抗性。在所有试验中,Be11细胞比MeWo细胞更具抗性。在联合暴露尤其是使用较高剂量阿霉素衍生物时,两种细胞系均呈现出有趣的效应,即随着浓度增加存活率降低而D(o)增加。阿克拉霉素-A(ACM-A)和吡柔比星降低了X射线照射后的恢复过程。因此,Be11细胞在ACM-A处理后的剂量修正因子(DMF)比MeWo细胞高四倍。低浓度ACM-A与低剂量X射线联合处理对两种细胞系均显示出超相加效应。吡柔比星的效应在大多数试验中仅为相加效应。与ACM-A相比,吡柔比星细胞毒性较小,治疗范围较大,导致较小的D(o)和Dq,且在低浓度时对两种细胞系均有超相加效应。对于患者的临床联合治疗,ACM-A可能比吡柔比星更合适。